672 related articles for article (PubMed ID: 27300147)
1. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
Piña-Garza JE; Rosenfeld W; Saeki K; Villanueva V; Yoshinaga H; Patten A; Williams B; Malhotra M
Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: A comparative study of Asian and non-Asian populations.
Nishida T; Lee SK; Wu T; Tiamkao S; Dash A
Epilepsia; 2019 Mar; 60 Suppl 1():47-59. PubMed ID: 30869168
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies.
Steinhoff BJ; Patten A; Williams B; Malhotra M
Epilepsia; 2020 Feb; 61(2):278-286. PubMed ID: 31944276
[TBL] [Abstract][Full Text] [Related]
5. Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.
Strzelczyk A; Willems LM; Willig S; Rosenow F; Bauer S
Expert Rev Clin Pharmacol; 2015; 8(6):733-40. PubMed ID: 26436331
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.
Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Clément JF; Wang X; Bagul M; Gee M; Zhu J; Squillacote D
Epilepsia; 2014 Jul; 55(7):1058-68. PubMed ID: 24867391
[TBL] [Abstract][Full Text] [Related]
8. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and tolerability of perampanel in Asian and non-Asian patients with epilepsy.
Tsai JJ; Ikeda A; Hong SB; Likasitwattanakul S; Dash A
Epilepsia; 2019 Mar; 60 Suppl 1():37-46. PubMed ID: 30869165
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of adjunctive Perampanel in a prospective, real-world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal-onset Epilepsy: Study 508.
Ravat S; Rohatgi A; Kulkarni R; Jabeen SA; Patil B; Dash A; Malhotra M
Epilepsia Open; 2024 Jun; 9(3):940-950. PubMed ID: 38124551
[TBL] [Abstract][Full Text] [Related]
11. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
[TBL] [Abstract][Full Text] [Related]
12. Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings.
Tsai JJ; Wu T; Leung H; Desudchit T; Tiamkao S; Lim KS; Dash A
Acta Neurol Scand; 2018 Apr; 137(4):378-391. PubMed ID: 29214650
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
[TBL] [Abstract][Full Text] [Related]
14. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Gidal BE; Ferry J; Majid O; Hussein Z
Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
[TBL] [Abstract][Full Text] [Related]
16. First add-on perampanel for focal-onset seizures: An open-label, prospective study.
Kim JH; Kim DW; Lee SK; Seo DW; Lee JW; Park HJ; Lee SA
Acta Neurol Scand; 2020 Feb; 141(2):132-140. PubMed ID: 31745975
[TBL] [Abstract][Full Text] [Related]
17. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
[TBL] [Abstract][Full Text] [Related]
18. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
19. A post hoc analysis of the long-term safety and efficacy of perampanel in Asian patients with epilepsy.
Inoue Y; Kaneko S; Hsieh PF; Meshram C; Lee SA; Aziz ZA; Nabangchang C; Dash A
Epilepsia; 2019 Mar; 60 Suppl 1():60-67. PubMed ID: 30869167
[TBL] [Abstract][Full Text] [Related]
20. Perampanel: Does it have broad-spectrum potential?
Potschka H; Trinka E
Epilepsia; 2019 Mar; 60 Suppl 1():22-36. PubMed ID: 29953584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
